A short case for PDL Biopharma: Simple math to understand why PDLI is worth less than $5 a share
In this note I will attempt to explain why I believe PDL Biopharma (NYSE: PDLI) may have substantial downside risk, why investors may be choosing to ignore this risk, why it only takes simple math to understand the firm's current value, and the catalysts for rapid price discovery in the shares. In short, if I am correct, PDLI may be vulnerable to a 40% sell-off to $5 a share or less from its current price of $8.25.
A (Very) Brief History
PDL Biopharma is a pharmaceutical royalty company. The shares have been well covered in these pages over the past...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|